血清1,5-脱水-D-山梨醇（1,5-AG）水平与心血管疾病风险的横断面研究

doi:10.12092/j.issn.1009-2501.2026.06.007

摘要/Abstract

摘要：

目的: 评估血清1,5-脱水-D-山梨醇（1,5-AG）水平与心血管疾病（cardiovascular diseases，CVDs）发生发展风险的相关性，探讨其作为CVDs预测标志物的潜在价值。方法: 采用横断面研究设计，纳入江苏省南京市及句容市873名社区人群。通过化学酶发光法检测受试者血清1,5-AG水平，收集人口学特征、体格检查及实验室检查指标，构建多因素Logistic风险模型分析其与CVDs事件的关联，通过受试者工作特征曲线（ROC）及决策曲线分析（DCA）评估预测效能。结果: 829名受试者（CVDs组166人，对照组663人）纳入分析。CVDs组血清1,5-AG水平显著低于对照组（0.11 [0.08，0.14] μmol/L vs. 0.12 [0.09，0.16] μmol/L，P=0.003）。经多因素Logistic回归分析校正后，建立的模型提示低血清1,5-AG水平与CVDs风险增加有关（OR=0.0111，P=0.039）。ROC分析显示，整合血清1,5-AG与常规指标的预测模型，具有良好的CVDs风险判别效能（AUC=0.797），对应灵敏度为0.681，特异度为0.780，约登指数（Youden index）为0.461。校正年龄和性别后，血清1,5-AG水平与10年心血管风险（r=?0.223）、出血性脑卒中（r=?0.260）和缺血性脑卒中（r=?0.274）均呈负相关，且P值均小于0.001。结论: 血清1,5-AG水平降低与CVDs风险独立相关，联合传统指标可提升预测效能，或为CVDs早期筛查提供新思路。

关键词: 1,5-AG, 心血管疾病, 缺血性脑卒中, 出血性脑卒中, 疾病风险

Abstract:

AIM: To evaluate the association between serum 1,5-anhydro-D-glucitol (1,5-AG) levels and the risk of developing cardiovascular diseases (CVDs), and to explore its potential value as a predictive biomarker for CVDs. METHODS: A cross-sectional study design was adopted, enrolling 873 community residents from Nanjing and Jurong, Jiangsu Province. Serum 1,5-AG levels were measured using a chemiluminescence enzyme immunoassay. Demographic characteristics, physical examination data, and laboratory parameters were collected. Multivariate logistic risk models were constructed to analyze the association between 1,5-AG levels and CVD events. Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curves and Decision Curve Analysis (DCA). RESULTS: A total of 829 subjects (166 in the CVDs group and 663 in the control group) were included in the final analysis. Serum 1,5-AG levels in the CVDs group were significantly lower than those in the control group (0.11 [0.08, 0.14] μmol/L vs. 0.12 [0.09, 0.16] μmol/L, P = 0.003). After adjustment via multivariate logistic regression analysis, the established model indicated that low serum 1,5-AG levels were associated with an increased risk of CVDs (OR = 0.0111, P = 0.039). ROC analysis showed that the predictive model integrating serum 1,5-AG with conventional indicators demonstrated good discriminative performance for CVD risk (AUC=0.797), with a sensitivity of 0.681, specificity of 0.780, and a Youden index of 0.461. After adjusting for age and sex, serum 1,5-AG levels were negatively correlated with 10-year cardiovascular risk (r=?0.223), hemorrhagic stroke (r=?0.260), and ischemic stroke (r=?0.274), with all P<0.001. CONCLUSION: Decreased serum 1,5-AG levels are independently associated with CVD risk. Combining 1,5-AG with traditional indicators can improve predictive performance, potentially providing a new perspective for early CVD screening.

Key words: 1,5-anhydro-D-glucitol, cardiovascular disease, ischemic stroke, hemorrhagic stroke, disease risk

中图分类号:

R54
R446.11

徐芊昊, 汪嘉辰, 付煜, 李悦, 杨涛. 血清1,5-脱水-D-山梨醇（1,5-AG）水平与心血管疾病风险的横断面研究[J]. 中国临床药理学与治疗学, 2026, 31(6): 782-788.

Qianhao XU, Jiachen WANG, Yu FU, Yue LI, Tao YANG. A cross-sectional study on the association between serum 1,5-anhydro-D-glucitol (1,5-AG) levels and cardiovascular disease risk[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 782-788.

图/表 6

参考文献 20

1	Liu L, Wan X, Liu J, et al. Increased 1, 5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy[J]. Diabetes Technol Ther, 2012, 14 (9): 756- 761. doi: 10.1089/dia.2012.0055
2	INTERNATIONAL DIABETES FEDERATION GUIDELINE DEVELOPMENT G. Guideline for management of postmeal glucose in diabetes[J]. Diabetes Res Clin Pract, 2014, 103 (2): 256- 268. doi: 10.1016/j.diabres.2012.08.002
3	国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告 2023概要[J]. 中国循环杂志, 2024, 39 (7): 625- 660.
4	Yamanouchi T, Shinohara T, Ogata N, et al. Common reabsorption system of 1, 5-anhydro-D-glucitol, fructose, and mannose in rat renal tubule[J]. Biochim Biophys Acta, 1996, 1291 (1): 89- 95. doi: 10.1016/0304-4165(96)00050-5
5	Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation, 2006, 114 (21): 2217- 2225. doi: 10.1161/CIRCULATIONAHA.105.607499
6	Yang S, Han Y, Yu C, et al. Development of a model to predict 10-year risk of ischemic and hemorrhagic stroke and ischemic heart disease using the China Kadoorie Biobank[J]. Neurology, 2022, 98 (23): e2307- e2317. doi: 10.1212/wnl.0000000000200139
7	中华医学会糖尿病学分会. 中国糖尿病防治指南(2024版)[J]. 中华糖尿病杂志, 2025, 17 (1): 136- 139.
8	中华医学会心血管病学分会代谢性心血管疾病学组中. 心血管病合并糖代谢异常患者心血管风险综合管理中国专家共识[J]. 中华心血管病杂志, 2021, 49 (7): 656- 672.
9	Tong Y, Liu F, Huang K, et al. Changes in fasting blood glucose status and incidence of cardiovascular disease: the China-PAR project[J]. J Diabetes, 2023, 15 (2): 110- 120. doi: 10.1111/1753-0407.13350
10	Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis[J]. BMJ, 2020, 370, m2297. doi: 10.1136/bmj.m2297
11	Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA)[J]. Diabetologia, 2003, 46 (9): 1190- 1198. doi: 10.1007/s00125-003-1167-8
12	Gyberg V, De Bacquer D, Kotseva K, et al. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology [J]. Eur Heart J, 2015, 36 (19): 1171-1177.
13	Yang ZJ, Liu J, Ge JP, et al. Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China national diabetes and metabolic disorders study[J]. Eur Heart J, 2012, 33 (2): 213- 220. doi: 10.1093/eurheartj/ehr205
14	Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis[J]. BMJ, 2016, 355, i5953. doi: 10.1136/bmj.i5953
15	Zhou M, Liu J, Hao Y, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-acute coronary syndrome project[J]. Cardiovasc Diabetol, 2018, 17 (1): 147. doi: 10.1186/s12933-018-0793-x
16	Ma X, Hao Y, Hu X, et al. 1, 5-anhydroglucitol is associated with early-phase insulin secretion in chinese patients with newly diagnosed type 2 diabetes mellitus[J]. Diabetes Technol Ther, 2015, 17 (5): 320- 326. doi: 10.1089/dia.2014.0346
17	Yamanouchi T, Akanuma Y. Serum 1, 5-anhydroglucitol (1, 5 AG): new clinical marker for glycemic control [J]. Diabetes Res Clin Pract, 1994, 24 (Suppl 1): S261-S268.
18	Watanabe M, Yoshida K, Higashiyama A, et al. Serum 1, 5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study[J]. Atherosclerosis, 2011, 216 (2): 477- 483. doi: 10.1016/j.atherosclerosis.2011.02.033
19	韩志勇. 血清1, 5-脱水葡萄糖醇的临床应用研究进展[J]. 实用检验医师杂志, 2015, 7 (1): 47- 50.
20	吴学毅, 邵丽娟, 田嘉嘉. 1, 5 -脱水葡萄糖醇在糖尿病管理中的应用[J]. 中华糖尿病杂志, 2022, 14 (增刊): 19- 22.

Variable	With CVDs (n=166)	Without CVDs (n=663)	P value
Male, n(%)	125 (75.3%)	363 (54.8%)	<0.001
Age(years)	49.95±9.99	39.66±11.54	<0.001
SBP(mmHg)	131.00 [120.62, 144.88]	120.50 [111.50, 131.00]	<0.001
DBP(mmHg)	88.00 [79.62, 97.00]	81.00 [74.75, 88.00]	<0.001
TC(mmol/L)	5.06 [4.45, 5.70]	4.66 [4.16, 5.35]	<0.001
TG(mmol/L)	1.75 [1.06, 2.62]	1.07 [0.72, 1.57]	<0.001
LDL-C(mmol/L)	3.25 [2.67, 3.74]	2.95 [2.49, 3.48]	0.002
HDL-C(mmol/L)	1.32 [1.12, 1.56]	1.48 [1.27, 1.71]	<0.001
Cr(μmol/L)	67.00 [60.00, 75.75]	64.00 [53.00, 73.00]	0.002
eGFR [mL/(min?1.73 m²)]	111.25 [95.68, 132.12]	117.52[102.25, 135.81]	0.028
HbA1c(%)	5.70 [5.40, 6.00]	5.40 [5.20, 5.70]	<0.001
FBG(mmol/L)	6.09 [5.67, 6.60]	5.64 [5.33, 6.06]	<0.001
Lp(α) (mg/L)	23.00 [13.00, 55.20]	26.15 [13.30, 59.45]	0.496
1,5-AG(μmol/L)	0.11 [0.08, 0.14]	0.12 [0.09, 0.16]	0.003

Variable	With CVDs (n=166)	Without CVDs (n=663)	P value
Male, n(%)	125 (75.3%)	363 (54.8%)	<0.001
Age(years)	49.95±9.99	39.66±11.54	<0.001
SBP(mmHg)	131.00 [120.62, 144.88]	120.50 [111.50, 131.00]	<0.001
DBP(mmHg)	88.00 [79.62, 97.00]	81.00 [74.75, 88.00]	<0.001
TC(mmol/L)	5.06 [4.45, 5.70]	4.66 [4.16, 5.35]	<0.001
TG(mmol/L)	1.75 [1.06, 2.62]	1.07 [0.72, 1.57]	<0.001
LDL-C(mmol/L)	3.25 [2.67, 3.74]	2.95 [2.49, 3.48]	0.002
HDL-C(mmol/L)	1.32 [1.12, 1.56]	1.48 [1.27, 1.71]	<0.001
Cr(μmol/L)	67.00 [60.00, 75.75]	64.00 [53.00, 73.00]	0.002
eGFR [mL/(min?1.73 m²)]	111.25 [95.68, 132.12]	117.52[102.25, 135.81]	0.028
HbA1c(%)	5.70 [5.40, 6.00]	5.40 [5.20, 5.70]	<0.001
FBG(mmol/L)	6.09 [5.67, 6.60]	5.64 [5.33, 6.06]	<0.001
Lp(α) (mg/L)	23.00 [13.00, 55.20]	26.15 [13.30, 59.45]	0.496
1,5-AG(μmol/L)	0.11 [0.08, 0.14]	0.12 [0.09, 0.16]	0.003

	OR (95%CI)	P value
Model 1
(Intercept)	0.4314(0.2732,0.6777)	<0.001
1,5-AG	0.0110(0.0003,0.3762)	0.014
Model 2
(Intercept)	0.0210(0.0075,0.0559)	<0.001
1,5-AG	0.0032(0.0001,0.1163)	0.002
Age	1.0796(1.0610,1.0995)	<0.001
Gender (male=0，female=1)	0.4620(0.3023,0.6959)	<0.001

	OR (95%CI)	P value
Model 1
(Intercept)	0.4314(0.2732,0.6777)	<0.001
1,5-AG	0.0110(0.0003,0.3762)	0.014
Model 2
(Intercept)	0.0210(0.0075,0.0559)	<0.001
1,5-AG	0.0032(0.0001,0.1163)	0.002
Age	1.0796(1.0610,1.0995)	<0.001
Gender (male=0，female=1)	0.4620(0.3023,0.6959)	<0.001

[1]	吴俊, 宋雨薇, 梁宏彪, 冯娟. 氧化三甲胺与糖尿病患者血管重塑[J]. 中国临床药理学与治疗学, 2026, 31(6): 774-781.
[2]	杨雅坤, 樊官伟, 李澜. 心脏淋巴管生成在心血管疾病中的最新研究进展[J]. 中国临床药理学与治疗学, 2026, 31(5): 658-665.
[3]	王晓丽, 邵静, 张薇, 田萍, 张雪侠, 刘长河, 李开言, 杨丹, 郭晓燕. 基于自噬流及CXCL12/CXCR4轴研究天麻钩藤饮对肝阳上亢证脑缺血再灌注大鼠模型的神经保护作用及机制[J]. 中国临床药理学与治疗学, 2025, 30(8): 1037-1048.
[4]	孙敏, 王洪娅, 何洪波, 祝之明, 高鹏. 代谢药物治疗心血管疾病的研究与进展[J]. 中国临床药理学与治疗学, 2025, 30(7): 984-997.
[5]	钱庆芳, 李文静, 李强. 靶向cGAS-STING通路与缺血性脑卒中治疗研究进展[J]. 中国临床药理学与治疗学, 2025, 30(5): 690-694.
[6]	崔涵雨, 胡长平. 巨噬细胞极化与心血管疾病研究进展[J]. 中国临床药理学与治疗学, 2025, 30(4): 548-555.
[7]	宋敏, 刁婷婷, 王一超, 刘璐怡, 齐琪琪, 毕晶晶, 朱乃亮, 乔新荣. 半夏及其有效成分在心血管疾病中的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(2): 251-264.
[8]	李东泽, 赵继义. PCSK9通过非血脂途径致动脉粥样硬化的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(10): 1400-1407.
[9]	宋秋英, 陶程娟, 吴之昊, 谢哲锋, 刘海俊, 陈彬彬. 基于药物基因多态性及血栓弹力图选择抗栓治疗对缺血性脑卒中复发的影响[J]. 中国临床药理学与治疗学, 2024, 29(9): 1035-1041.
[10]	孟倩, 王依玟, 崔娜, 白敏, 杨乐, 丁一. 单细胞多组学测序技术在缺血性脑卒中研究中的应用[J]. 中国临床药理学与治疗学, 2024, 29(6): 690-699.
[11]	李梅, 李强. 靶向Nrf2-铁死亡通路与缺血性脑卒中后脑损伤治疗研究进展[J]. 中国临床药理学与治疗学, 2024, 29(2): 188-197.
[12]	王坤, 许佩佩, 周兰兰, 鲁晟. 人参皂苷Rg1调控Epac1/Rap1信号通路对缺血性脑卒中大鼠神经保护作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 721-727.
[13]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[14]	秦文秀, 许军峰, 杨婷, 王坪霏. 丹参酮IIA治疗缺血性脑卒中后神经损伤的信号通路研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 705-713.
[15]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.